Y. -jun Li, Danelishvili, L., Wagner, D., Petrofsky, M., and Bermudez, L. E.,
“Identification of virulence determinants of Mycobacterium avium that impact on the ability to resist host killing mechanisms.”,
Journal of medical microbiology, vol. 59, no. Pt 1, pp. 8-16, 2010.
L. E. Bermudez, Kolonoski, P., Petrofsky, M., Wu, M., Inderlied, C. B., and Young, L. S.,
“Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.”,
The Journal of infectious diseases, vol. 187, no. 12, pp. 1977-80, 2003.
D. Wagner, Sangari, F. J., Kim, S., Petrofsky, M., and Bermudez, L. E.,
“Mycobacterium avium infection of macrophages results in progressive suppression of interleukin-12 production in vitro and in vivo.”,
Journal of leukocyte biology, vol. 71, no. 1, pp. 80-8, 2002.
Y. Li, Miltner, E., Wu, M., Petrofsky, M., and Bermudez, L. E.,
“A Mycobacterium avium PPE gene is associated with the ability of the bacterium to grow in macrophages and virulence in mice.”,
Cellular microbiology, vol. 7, no. 4, pp. 539-48, 2005.
L. E. Bermudez, Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., and Young, L. S.,
“SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.”,
Antimicrobial agents and chemotherapy, vol. 48, no. 9, pp. 3556-8, 2004.